Structure-Guided Evolution of Potent and Selective Chk1 Inhibitors Through Scaffold Morphing.
Reader, J.C., Matthews, T.P., Klair, S., Cheung, K.M.J., Scanlon, J., Proisy, N., Addison, G., Ellard, J., Piton, N., Taylor, S., Cherry, M., Fisher, M., Boxall, K., Burns, S., Walton, M.I., Westwood, I.M., Hayes, A., Eve, P., Valenti, M., De Haven Brandon, A., Box, G., Van Montfort, R.L.M., Williams, D.H., Aherne, G.W., Raynaud, F.I., Eccles, S.A., Garrett, M.D., Collins, I.(2011) J Med Chem 54: 8328
- PubMed: 22111927 
- DOI: 10.1021/jm2007326
- Primary Citation of Related Structures:  
2YM6, 2YM7, 2YM8, 2YM3, 2YM4, 2YM5 - PubMed Abstract: 
Pyrazolopyridine inhibitors with low micromolar potency for CHK1 and good selectivity against CHK2 were previously identified by fragment-based screening. The optimization of the pyrazolopyridines to a series of potent and CHK1-selective isoquinolines de ...